Compounded Anti-Infective Compositions for Skin and Respiratory Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective compositions and methods to treat or prevent the progression and reoccurrence of bacterial infections and fungal infections affecting the skin, respiratory system, or feet, as current treatments are inadequate.
Innovation Solution
A method involving a treatment composition formulated with a diluent and a dry powder containing anti-infective agents like streptomycin, colistimethate, clindamycin, or mupirocin, applied topically to infected areas, with the composition comprising between 1% to 10% streptomycin by weight, and optionally including additional anti-infective agents, to be administered through various routes such as topical application, nebulization, or foot baths.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for bacterial infections, then treatment is provided, but the treatments are inadequate and fail to effectively prevent progression and reoccurrence
Solution Approach 1:
The treatment is segmented into multiple components: a base composition containing anti-infective agents (streptomycin, colistimethate, clindamycin, or mupirocin) and a diluent that can be customized based on the infection site. The base composition provides reliable antimicrobial activity while the diluent selection (cream, ointment, emulsion, gel, sterile aqueous solution) adapts the treatment to specific anatomical locations and infection types.
Solution Approach 2:
The patent applies parameter changes by controlling the concentration of streptomycin (1% to 10% by weight) and adjusting the formulation type (topical, nebulized, foot bath) based on the infection site. This allows the same active ingredients to be effectively adapted for different body surfaces and infection severities, improving both reliability and adaptability.
2Quantity of substance
If anti-infective agents are applied topically to infected areas, then direct delivery to infection site is achieved, but customization for different infection sites and types is limited
Solution Approach 1:
The base composition serves multiple functions across different infection sites and types. The same core formulation (anti-infective agents in diluent) can be applied topically to skin infections, nebulized for respiratory infections, or used in foot baths for fungal infections, making the treatment universally applicable while maintaining site-specific effectiveness through administration route customization.
3Manufacturing precision
If treatment composition is formulated with specific concentration ranges, then effective dosage is achieved, but flexibility in adjusting for different infection severities is reduced
Solution Approach 1:
The formulation allows dynamic adjustment within the 1% to 10% streptomycin concentration range based on infection severity and site. The patent specifies this range to provide both manufacturing precision for safety and flexibility for clinical adaptation, enabling practitioners to select appropriate concentrations for mild versus severe infections while maintaining controlled, effective dosing.
Data Source
AI summary
The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as streptomycin and one or more of colistimethate, clindamycin, or mupirocin.